中国医疗保险2024,Issue(12) :29-32.DOI:10.19546/j.issn.1674-3830.2024.12.005

我国创新医药技术的多层次保障体系探讨

Discussions on the Multi-Level Security System of Innovative Medical and Pharmaceutical Technology in China

陶立波 王芳旭
中国医疗保险2024,Issue(12) :29-32.DOI:10.19546/j.issn.1674-3830.2024.12.005

我国创新医药技术的多层次保障体系探讨

Discussions on the Multi-Level Security System of Innovative Medical and Pharmaceutical Technology in China

陶立波 1王芳旭1
扫码查看

作者信息

  • 1. 北京大学医学部卫生政策与技术评估中心 北京 100029
  • 折叠

摘要

目的:探讨我国创新医药的多层次保障体系建设.方法:基于理论分析与政策经验,探讨基本医保对创新医药的支持作用和局限性,提出专项保障机制对于创新医药初期临床导入阶段的风险管控和财务支付的重要意义,并分析了商业医保与专项基金这两种创新医药专项保障机制运行模式的特点与利弊.结论:建立创新医药的专项保障机制,理顺其与基本医保的衔接配合,从而建立多层次保障体系,对于我国创新医药的发展和应用具有重要意义.

Abstract

Objective:The paper explores the construction of a multi-level security system for innovative pharmaceuticals in China. Methods:Based on theoretical analysis and policy experience,this paper discussed the role and limitations of basic medical insurance supporting innovative drugs,put forward the importance of the special security mechanism for risk control and financial payment in the initial clinical introduction stage of innovative drugs,and analyzed the characteristics,advantages and disadvantages of the operation modes of commercial medical insurance and special funds. Conclusion:It is of great significance for the development and application of innovative drugs in China to establish a special security mechanism for innovative drugs and clarify its connection and cooperation with basic medical insurance,so as to establish a multi-level security system.

关键词

创新医药/上市初期/专项保障/多层次保障体系

Key words

innovative drugs/early stage of marketing/special security/multi-level security system

引用本文复制引用

出版年

2024
中国医疗保险
中国医疗保险研究会

中国医疗保险

影响因子:0.492
ISSN:1674-3830
段落导航相关论文